MGMT and neoplasm: Tumor heterogeneity and patient-specific factors such as MGMT promoter methylation status should be considered when assessing the potential generalization of our findings, including the emergence of resistance mechanisms, intricacies in combining multiple therapeutic agents, and the potential for side effects.